治疗接受COVID-19疫苗接种的原发性免疫性血栓塞缩症患者的挑战:一项回顾性研究
Huiping Xu1, Beibei Zhang2, Linjun Xie2,3
1Department of Clinical Nutrition, The First Hospital of Putian City, Putian 351100, Fujian, P.R. China.
Open medicine (Warsaw, Poland)
|April 8, 2024
概括
接种COVID-19疫苗可能会影响原发性免疫血栓塞缩症 (ITP) 的治疗. 与未接种疫苗的患者相比,接种ITP疫苗的患者对初始治疗的短期反应较低.
科学领域:
- 血液学 血液学 血液学
- 免疫学 免疫学 免疫学
- 疫苗学 疫苗学 疫苗学
背景情况:
- 由于COVID-19的流行,需要大规模的疫苗接种工作.
- 初级免疫血小板缺血 (ITP) 管理在COVID-19疫苗接种后提出了新的挑战.
研究的目的:
- 为了比较 de novo ITP 接受COVID-19 疫苗接种的患者与未接种疫苗的患者的治疗反应.
- 评估初始ITP治疗策略在接种疫苗和未接种疫苗的队列中的有效性.
主要方法:
- 一项比较性研究,涉及25名COVID-19疫苗接种后的新出现的ITP患者 (第一组) 和25名大流行前的对照 (第二组).
- 统计分析包括曼·惠特尼U测试和费舍尔精确测试,以比较治疗结果.
- 血小板计数和需要联合治疗是关键的结果指标.
主要成果:
- 第1组 (接种疫苗) 在第3天和第7天的血小板数量中位数显著降低,相比于第2组 (未接种疫苗).
- 第1组的患者表现出对单独治疗葡萄糖皮质激素的短期反应不足.
- 更多的接种疫苗的患者需要二线或组合疗法 (IVIG,TPO-RAs,rituximab).
结论:
- 在 de novo ITP 患者中,COVID-19 疫苗接种可能与一线治疗的响应率降低有关.
- 研究结果表明,对接种疫苗的人群的ITP管理策略有潜在的影响.
- 需要进一步的研究来证实这些观察,并阐明潜在的机制.
相关概念视频
Blood Transfusion and Agglutination
Blood transfusion is a therapeutic measure to restore the blood volume after extensive blood loss due to an accident or a medical procedure. Blood transfusion involves drawing a certain amount of blood from a suitable donor and infusing it into the recipient.
History
The history of blood transfusion dates back to the 17th century, when early attempts were made in animals. In 1818 James Blundell, a British doctor, performed the first successful human blood transfusion. Later in 1900, Karl...
History
The history of blood transfusion dates back to the 17th century, when early attempts were made in animals. In 1818 James Blundell, a British doctor, performed the first successful human blood transfusion. Later in 1900, Karl...
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Immunodeficiency Diseases
Immunodeficiency disorders are conditions in which the immune system's ability to fight infectious disease and cancer is compromised or entirely absent. The immune system comprises a complex network of cells, tissues, and organs that work together to protect the body from potentially harmful invaders. When this system is deficient or not functioning properly, it leaves the body susceptible to infections, diseases, or other complications.
There are three main causes of immunodeficiency disorders...
There are three main causes of immunodeficiency disorders...
Endocarditis III: Medical Management
Infective endocarditis management involves a multifaceted approach encompassing infection prevention, lifestyle modifications, pharmacological therapy, and surgical management.Infection Prevention:Hand Hygiene: Thorough handwashing is crucial to prevent the spread of infection. Hand hygiene should be performed regularly, especially before and after using the restroom.Oral Hygiene: Good oral hygiene is essential. It includes brushing teeth immediately after waking up and before bed, flossing...
Myocarditis III: Medical Management
Myocarditis: Comprehensive Medical ManagementMyocarditis, the heart muscle inflammation, requires a comprehensive medical management strategy that addresses the underlying cause, provides supportive care, manages symptoms, and reduces cardiac workload.Infections and Autoimmune CausesAdminister appropriate antimicrobial therapy when an infectious agent causes myocarditis. For instance, penicillin treats infections caused by Group A Streptococcus. In cases where autoimmune processes are...
Venous Thrombosis III: Interprofessional Care
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...


